82 FR 42706 - Notification of a Public Meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis (Commission)

EXECUTIVE OFFICE OF THE PRESIDENT
Office of National Drug Control Policy

Federal Register Volume 82, Issue 174 (September 11, 2017)

ONDCP announces the third meeting of the President's Commission on Combating Drug Addiction and the Opioid Crisis to advance the Commission's work on drug issues and the opioid crisis per Executive Order 13784. The meeting will consist of statements to the Commission from invited government, nonprofit, and business organizations regarding Innovative Pain Management and Prevention Measures for Diversion followed by discussion of the issues raised.

[Federal Register Volume 82, Number 174 (Monday, September 11, 2017)]
[Notices]
[Page 42706]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-19186]


=======================================================================
-----------------------------------------------------------------------

EXECUTIVE OFFICE OF THE PRESIDENT

Office of National Drug Control Policy


Notification of a Public Meeting of the President's Commission on 
Combating Drug Addiction and the Opioid Crisis (Commission)

AGENCY: Office of National Drug Control Policy (ONDCP), Executive 
Office of the President.

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: ONDCP announces the third meeting of the President's 
Commission on Combating Drug Addiction and the Opioid Crisis to advance 
the Commission's work on drug issues and the opioid crisis per 
Executive Order 13784. The meeting will consist of statements to the 
Commission from invited government, nonprofit, and business 
organizations regarding Innovative Pain Management and Prevention 
Measures for Diversion followed by discussion of the issues raised.

DATES: The Commission meeting will be held on Wednesday September 27, 
2017 from 12:30 p.m. until approximately 2:30 p.m. (Eastern Time).

ADDRESSES: The meeting will be held at the Eisenhower Executive Office 
Building, Room 350, in the Executive Office of the President in 
Washington, DC. It will be open to the public through livestreaming on 
https://www.whitehouse.gov/live.

FOR FURTHER INFORMATION CONTACT: General information concerning the 
Commission and its meetings can be found on ONDCP's Web site at https://www.whitehouse.gov/ondcp/presidents-commission. Any member of the 
public who wishes to obtain information about the Commission or its 
meetings that is not already on ONDCP's Web site or who wishes to 
submit written comments for the Commission's consideration may contact 
Michael Passante, Designated Federal Officer (DFO) via email at 
[email protected] or telephone at (202) 395-6709. Please note 
that ONDCP may post such written comments publicly on our Web site, 
including names and contact information that are submitted. There will 
not be oral comments from the public at the meeting. Requests to 
accommodate disabilities with respect to livestreaming or otherwise 
should also be sent to that email address, preferably at least 10 days 
prior to the meeting to allow time for processing.

SUPPLEMENTARY INFORMATION: The Commission was established in accordance 
with E.O. 13784 of March 29, 2017, the Commission's charter, and the 
provisions of the Federal Advisory Committee Act (FACA), as amended, 5 
U.S.C. App. 2, to obtain advice and recommendations for the President 
regarding drug issues. The Executive Order, charter, and information on 
the Members of the Commission are available on ONDCP's Web site. The 
Commission will function solely as an advisory body and will make 
recommendations regarding policies and practices for combating drug 
addiction with particular focus on the current opioid crisis in the 
United States. The Commission's final report is due October 1, 2017 
unless there is an extension. Per E.O. 13784, the Commission shall:
    a. Identify and describe the existing Federal funding used to 
combat drug addiction and the opioid crisis;
    b. assess the availability and accessibility of drug addiction 
treatment services and overdose reversal throughout the country and 
identify areas that are underserved;
    c. identify and report on best practices for addiction prevention, 
including healthcare provider education and evaluation of prescription 
practices, collaboration between State and Federal officials, and the 
use and effectiveness of State prescription drug monitoring programs;
    d. review the literature evaluating the effectiveness of 
educational messages for youth and adults with respect to prescription 
and illicit opioids;
    e. identify and evaluate existing Federal programs to prevent and 
treat drug addiction for their scope and effectiveness, and make 
recommendations for improving these programs; and
    f. make recommendations to the President for improving the Federal 
response to drug addiction and the opioid crisis.

    Dated: September 6, 2017.
Michael Passante,
Deputy General Counsel, Designated Federal Officer.
[FR Doc. 2017-19186 Filed 9-8-17; 8:45 am]
 BILLING CODE 3280-F5-P